VYNE Therapeutics Inc.

NasdaqCM VYNE

VYNE Therapeutics Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2024: 100.00%

VYNE Therapeutics Inc. Gross Profit Margin is 100.00% for the Trailing 12 Months (TTM) ending September 30, 2024, a 0.00% change year over year. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.

VYNE Therapeutics Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2023 was 100.00%, a 49.51% change year over year.
VYNE Therapeutics Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2022 was 66.88%, a -18.65% change year over year.
VYNE Therapeutics Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2021 was 82.21%, a -13.34% change year over year.
VYNE Therapeutics Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2020 was 94.86%.

Key data

Date	Gross Profit Margin	Operating Income Margin	EBT Margin	Net Income Margin

NasdaqCM: VYNE

VYNE Therapeutics Inc.

CEO	Mr. David T. Domzalski
IPO Date	Jan. 25, 2018
Location	United States
Headquarters	520 U.S. Highway 22
Employees	10
Sector	Health Care
Industries Pharmaceuticals Biotechnology Cosmetics

Description

VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.

Key trends

Past 5 years